Study characteristics
|
Study ID
|
Unique identifier for each study retrieved.
|
Trial acronym/first author
|
Either the trial acronym (if applicable, e.g. HOPE, VALUE) or first author of the primary study report if not (e.g. Smith AB et al.).
|
Year
|
Year of primary study publication.
|
Study design
|
Placebo-controlled, active comparator-controlled or PROBE design.
|
Duration of follow-up
|
Time period (in months) over which participants underwent follow-up
|
Age
|
Mean age of all patients included in analysis.
|
Sex
|
Number (%) of male study participants.
|
Hypertension
|
Number (%) of study participants with hypertension.
|
Heart failure
|
Number (%) of study participants with heart failure.
|
Diabetes
|
Number (%) of study participants with diabetes.
|
Ischaemic heart disease
|
Number (%) of study participants with ischaemic heart disease.
|
Loss to follow-up
|
Number (%) of study participants lost to follow-up
|
Revascularisation
|
Number (%) of study participants that underwent invasive coronary revascularisation
|
Concomitant drug therapy
|
Number (%) of study participants receiving other cardiovascular agents (β-blockers, calcium channel blockers, etc.)
|
Exposures and outcomes for each group
|
Group class
|
Class of agent in the intervention and comparator arms (i.e. ACEi or ARB and placebo or active comparator).
|
Group agent
|
Identity of agent given to participants randomised to the intervention and comparator arms
|
n in group
|
Number in intervention and comparator arms (included in final analysis)
|
Baseline SBP
|
Baseline systolic blood pressure (mmHg) in each group. If multiple are provided (e.g. sitting, ambulatory, supine, etc.) sitting/clinic measurement will be used.
|
Follow-up SBP
|
Systolic blood pressure measured during follow-up in each group (mmHg). Any SBP measured at ‘steady-state’ during follow-up, or SBP averaged across visits may be included. If serial measurements are reported, the last measurement will be extracted. SBP after the first-dose of the medication will not be included.
|
Within-group difference in SBP
|
The within-group change in SBP from baseline to follow-up either directly reported or calculated as per Fig. 2. Directly reported differences will supersede calculated values.
|
Between-group difference in SBP
|
The between-group difference in SBP change, either directly reported or calculated as per Fig. 2. Directly-reported differences will supersede calculated values.
|
Baseline DBP
|
Baseline diastolic blood pressure (mm Hg) in each group. If multiple are provided (e.g. sitting, ambulatory, supine, etc.) sitting/clinic measurement will be used.
|
Follow-up DBP
|
Diastolic blood pressure measured during follow-up in each group (mm Hg). Any DBP measured at ‘steady-state’ during follow-up, or SBP averaged across visits may be included. If serial measurements are reported, the last measurement will be extracted. DBP after the first-dose of the medication will not be included.
|
Within-group difference in DBP
|
The within-group change in DBP from baseline to follow-up either directly reported or calculated as per Fig. 2. Directly-reported differences will supersede calculated values.
|
Between-group difference in DBP
|
The between-group difference in DBP change either directly reported or calculated as per Fig. 2. Directly reported differences will supersede calculated values.
|
All-cause mortality
|
The total number of deaths, of any cause, that occur in each group during follow-up. If the denominator is different to ‘n in group’, this must be specified.
|
Cardiovascular mortality
|
The number of cardiovascular deaths that occur in each group during follow-up. If the denominator is different to ‘n in group’, this must be specified.
|
Definition of cardiovascular mortality
|
Study definition of cardiovascular mortality, as per Table 2, below.
|
Myocardial infarction
|
The number of myocardial infarctions that occur in each group during follow-up. If the denominator is different to ‘n in group’, this must be specified.
|
Definition of myocardial infarction
|
Study definition of cardiovascular mortality, as per Table 2, below.
|
Stroke
|
The number of strokes that occur in each group during follow-up. If the denominator is different to ‘n in group’, this must be specified.
|
Definition of stroke
|
Study definition of stroke, as per Table 2, below.
|